Detalhe da pesquisa
1.
Evaluating the Efficacy of Crisaborole Using the Atopic Dermatitis Severity Index and Percentage of Affected Body Surface Area.
Acta Derm Venereol
; 100(13): adv00170, 2020 Jun 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32318744
2.
Topical Agents for the Treatment of Atopic Dermatitis
J Drugs Dermatol
; 19(1): 50-64, 2020 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31985912
3.
Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial.
J Allergy Clin Immunol
; 144(5): 1274-1289, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31419544
4.
Direct and Indirect Effects of Crisaborole Ointment on Quality of Life in Patients with Atopic Dermatitis: A Mediation Analysis.
Acta Derm Venereol
; 99(9): 756-761, 2019 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30896779
5.
Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.
BMC Dermatol
; 16(1): 15, 2016 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27716172
6.
Skin permeation and penetration of crisaborole when coapplied with emollients.
J Am Acad Dermatol
; 83(6): 1801-1803, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33069458
7.
Randomized Pilot Clinical Trial of Tofacitinib Solution for Plaque Psoriasis: Challenges of the Intra-Subject Study Design.
J Drugs Dermatol
; 14(8): 777-84, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26267721
8.
Relationship between atorvastatin dose and the harm caused by torcetrapib.
J Lipid Res
; 53(11): 2436-42, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22941786
9.
Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years.
Paediatr Drugs
; 24(2): 175-183, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35292919
10.
Predictors of Systemic Exposure to Topical Crisaborole: A Nonlinear Regression Analysis.
J Clin Pharmacol
; 60(10): 1344-1354, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32433779
11.
Phase 1 study of crisaborole in Japanese healthy volunteers and patients with atopic dermatitis.
J Dermatol
; 47(1): 25-32, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31657024
12.
Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1).
Am J Clin Dermatol
; 21(2): 275-284, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-32212104
13.
Systemic Tofacitinib Concentrations in Adult Patients With Atopic Dermatitis Treated With 2% Tofacitinib Ointment and Application to Pediatric Study Planning.
J Clin Pharmacol
; 59(6): 811-820, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30556911
14.
Tolerability of Topical Treatments for Atopic Dermatitis.
Dermatol Ther (Heidelb)
; 9(1): 71-102, 2019 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-30680551
15.
Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups.
Am J Clin Dermatol
; 20(5): 711-723, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31264114
16.
Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies.
Rheumatol Ther
; 5(2): 567-582, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-30414064
17.
Effectiveness of Lipid-Lowering Statin Therapy in Patients With and Without Psoriasis.
Clin Drug Investig
; 37(8): 775-785, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28573499
18.
The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study.
J Dermatol Sci
; 88(1): 36-45, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28558978